Tubulin inhibitor 41 

Tubulin inhibitor 41 (Compd D19), a promising anti-GBM (glioblastoma) lead compound and tublin inhibitor with BBB permeability, induces G2/M phase arrest, resulted in cell apoptosis and inhibits the migration of U87 cells^[1].

Tubulin inhibitor 41 (Compd D19) displays positive antiproliferative activity against U87 cancer cell line (IC₅₀ = 0.90 ± 0.03 μM). Tubulin inhibitor 41 (Compd D19) could degrade the intracellular tubulin skeletons^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tubulin inhibitor 41 (Compd D19, 5 mg/kg and 10 mg/kg) dose-dependently inhibits the tumor growth of orthotopic glioma xenografts model (GL261-Luc) and effectively prolonged the survival time of mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

313.35

C₂₀H₁₅N₃O

2770273-12-4

N#CC(C1C2=CC=CC=C2)=C(N)OC3=C1C=CC4=C3N=C(C)C=C4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Haoyi Yang, et al. Novel 4-Aryl-4H-chromene derivative displayed excellent in vivo anti-glioblastoma efficacy as the microtubule-targeting agent. Eur J Med Chem. 2024 Feb 8:267:116205.  [Content Brief]